Witzigmann Helmut, Berr Frieder, Ringel Ulrike, Caca Karel, Uhlmann Dirk, Schoppmeyer Konrad, Tannapfel Andrea, Wittekind Christian, Mossner Joachim, Hauss Johann, Wiedmann Marcus
Department of Surgery II, University of Leipzig, Leipzig, Germany.
Ann Surg. 2006 Aug;244(2):230-9. doi: 10.1097/01.sla.0000217639.10331.47.
First, to analyze the strategy for 184 patients with hilar cholangiocarcinoma seen and treated at a single interdisciplinary hepatobiliary center during a 10-year period. Second, to compare long-term outcome in patients undergoing surgical or palliative treatment, and third to evaluate the role of photodynamic therapy in this concept.
Tumor resection is attainable in a minority of patients (<30%). When resection is not possible, radiotherapy and/or chemotherapy have been found to be an ineffective palliative option. Recently, photodynamic therapy (PDT) has been evaluated as a palliative and neoadjuvant modality.
Treatment and outcome data of 184 patients with hilar cholangiocarcinoma were analyzed prospectively between 1994 and 2004. Sixty patients underwent resection (8 after neoadjuvant PDT); 68 had PDT in addition to stenting and 56 had stenting alone.
The 30-day death rate after resection was 8.3%. Major complications occurred in 52%. The overall 1-, 3-, and 5-year survival rates were 69%, 30%, and 22%, respectively. R0, R1, and R2 resection resulted in 5-year survival rates of 27%, 10%, and 0%, respectively. Multivariate analysis identified R0 resection (P < 0.01), grading (P < 0.05), and on the limit to significance venous invasion (P = 0.06) as independent prognostic factors for survival. PDT and stenting resulted in longer median survival (12 vs. 6.4 months, P < 0.01), lower serum bilirubin levels (P < 0.05), and higher Karnofsky performance status (P < 0.01) as compared with stenting alone. Median survival after PDT and stenting, but not after stenting alone, did not differ from that after both R1 and R2 resection.
Only complete tumor resection, including hepatic resection, enables long-term survival for patients with hilar cholangiocarcinoma. Palliative PDT and subsequent stenting resulted in longer survival than stenting alone and has a similar survival time compared with incomplete R1 and R2 resection. However, these improvements in palliative treatment by PDT will not change the concept of an aggressive resectional approach.
第一,分析在一个综合性肝胆中心10年间诊治的184例肝门部胆管癌患者的治疗策略。第二,比较接受手术或姑息治疗患者的长期预后。第三,评估光动力疗法在这一治疗理念中的作用。
少数患者(<30%)可实现肿瘤切除。当无法进行切除时,放疗和/或化疗已被证明是无效的姑息治疗选择。最近,光动力疗法(PDT)已被评估为一种姑息和新辅助治疗方式。
对1994年至2004年间184例肝门部胆管癌患者的治疗及预后数据进行前瞻性分析。60例患者接受了手术切除(8例在新辅助PDT后);68例除支架置入外还接受了PDT,56例仅接受了支架置入。
切除术后30天死亡率为8.3%。主要并发症发生率为52%。总体1年、3年和5年生存率分别为69%、30%和22%。R0、R1和R2切除的5年生存率分别为27%、10%和0%。多因素分析确定R0切除(P < 0.01)、分级(P < 0.05)以及接近显著水平的静脉侵犯(P = 0.06)为生存的独立预后因素。与单纯支架置入相比,PDT联合支架置入导致中位生存期更长(12个月对6.4个月,P < 0.01)、血清胆红素水平更低(P < 0.05)以及卡氏功能状态评分更高(P < 0.01)。PDT联合支架置入后的中位生存期与R1和R2切除后的中位生存期无差异,但单纯支架置入后的中位生存期与之不同。
只有包括肝切除在内的完整肿瘤切除才能使肝门部胆管癌患者获得长期生存。姑息性PDT及随后的支架置入比单纯支架置入导致更长的生存期,并且与不完全的R1和R2切除具有相似的生存时间。然而,PDT在姑息治疗方面的这些改善不会改变积极手术切除方法的理念。